3/26/2014 9:53:54 AM
BUSAN, South Korea & SAN FRANCISCO & STRASBOURG, France & HONG KONG--(BUSINESS WIRE)--Regulatory News: Transgene SA (Paris:TNG), Lee’s Pharmaceutical (HKEx: 0950) and SillaJen today unveiled their late-stage clinical development plan for Pexa-Vec (JX-594/TG6006) oncolytic immunotherapy. The companies plan to initiate a global Phase 3 study in the first-line treatment of advanced hepatocellular carcinoma (HCC, liver cancer) patients, as well as several additional Phase 1/2 trials in different cancers, both as a single agent and in combination with a variety of other treatments, including immunotherapies such as immune checkpoint inhibitors. In addition, the partners plan to undertake several exploratory trials of intravenous infusion therapy in various tumor types, including renal, breast and soft tissue sarcoma.
Help employers find you! Check out all the jobs and post your resume.
comments powered by